bd211
Gene therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2021 (NCT05015920)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hemoglobin subunit muSupplementation
HBM supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06465550 | Phase 1 | Jan 5, 2024 | Shanghai BDgene Co., Ltd., Sun Yat-Sen University |
| NCT05773729 | N/A | Mar 31, 2023 | Jiao Tong University, Shanghai BDgene Co., Ltd. |
| NCT05776173 | N/A | Mar 31, 2023 | Jiao Tong University, Shanghai BDgene Co., Ltd. |
| NCT05015920 | N/A | Apr 1, 2021 | People's Liberation Army of China, Shanghai BDgene Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai BDgene Co., Ltd. | For profit | 4 | 4 | 2 | 2021 |
| Jiao Tong University | Academic/Hospital | 2 | 0 | 1 | 2023 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1